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doi:10.1016/j.jtcvs.2007.12.0111014 The Journal of Thoracic and CaObjectives: Lung cancer is associated with a significant rate of locoregional recur-
rence after surgical resection, particularly when nonanatomic wedge resections are
performed. The primary aim of this study was to assess the feasibility of a microsphere
drug delivery system to locally deliver chemotherapy and prevent the establishment
and growth of lung cancer cells and establish proof of concept for a potential future
approach to target occult microscopic disease remaining at the surgical resection
margin.
Methods: Poly-(D,L-lactic-co-glycolic acid) (PLGA) microspheres loaded with the
antineoplastic agent paclitaxel were prepared and tested for antitumor efficacy in an
in vitro cell proliferation assay for tumor inhibition and induction of apoptosis. The
in vivo prevention of Lewis lung carcinoma cell establishment and growth in subcu-
taneous tissues of mice was also assessed by comparing 4 treatment groups: Lewis
lung carcinoma cells alone, Lewis lung carcinoma cells combined with 100 3 106
unloaded (carrier alone) PLGA microspheres, and Lewis lung carcinoma cells com-
bined with 50 3 106 or 100 3 106 paclitaxel-loaded PLGA microspheres. After the
coinjection of Lewis lung carcinoma cells with or without microspheres, in vivo tumor
growth was monitored, and tumor weight was recorded on death.
Results: Paclitaxel-loaded PLGA microspheres were found to effectively prevent
growth of tumor cells in culture through the induction of apoptosis. Similarly, pacli-
taxel-loaded PLGA microspheres significantly inhibited tumor growth in vivo at both
the 50 3 106 and 100 3 106 microsphere dose (0.497 6 0.183 and 0.187 6 0.083 g
total tumor weight, respectively) compared with 2.91 6 0.411 g for Lewis lung car-
cinoma cells with unloaded microspheres and 3.37 6 0.433 g for untreated tumor
(P , .001). Toxicity was not clinically apparent in any animal treated with pacli-
taxel-loaded PLGA microspheres.
Conclusions: Paclitaxel-loaded PLGA microspheres induce tumor apoptosis and in-
hibit the establishment and growth of lung cancer cells both in vitro and in vivo with-
out obvious systemic toxicity. By using models consistent with localized microscopic
tumor burdens, these results suggest that local delivery of paclitaxel through a micro-
sphere system might lead to an effective future method of decreasing local tumor
recurrence in non–small cell lung cancer when applied to the surgical margins at
risk for microscopic tumor foci. Such an approach might be particularly efficacious
after wedge resection in the setting of poor pulmonary reserve or significant comor-
bidity, where local recurrence rates are increased and acceptable alternative treatment
options are limited.
T
he Lung Cancer Study Group demonstrated that the locoregional recurrence
rate in patients with stage I lung cancer (T1 N0 M0) is increased 3-fold after
limited resections compared with that after lobectomy.1 Landreneau and col-
leagues2 demonstrated similar results in which local recurrence rates increased from
9% after lobectomy to 24% when more limited wedge resections were performed
because of poor pulmonary reserve. Previous approaches aimed at decreasing localrdiovascular Surgery c May 2008
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BSA 5 bovine serum albumin
DMEM 5 Dulbecco’s modified Eagle’s medium
DMSO 5 dimethyl sulfoxide
ELISA 5 enzyme-linked immunosorbent assay
FBS 5 fetal bovine serum
IC50 5 amount of paclitaxel necessary to inhibit the
growth of lung cancer tumor cells by 50%
LLC 5 Lewis lung carcinoma cell
MTT 5 3-(4,5-dimethylthiazol-2-yl)
2,5-diphenyltetrazolium bromide
Pax-PLGA 5 paclitaxel-loaded
poly-(D,L-lactic-co-glycolic acid)
PI 5 propidium iodide
SEM 5 scanning electron microscopy
recurrence rates after lung resection have used external radi-
ation treatment or placement of radioactive seeds along the
stapled surgical margin but have met with limited success be-
cause of concerns about radiation risks to both the patient and
operating personnel, impaired postoperative healing, and in-
creased radiation fibrosis to the bystander lung tissue.3,4 Sim-
ilarly, the toxicity of systemic chemotherapy has outweighed
the potential benefit of improved local control in this select
population. Therefore the current therapy of choice for local
tumor recurrence is repeat surgical resection when possible.
However, because of tumor location and patient morbidity,
only one third of patients are candidates for resection, and
if distant recurrence develops, less than 10% of patients
will have their disease controlled. More than half of all deaths
after resection are attributed to recurrent disease.5,6
Therefore the prevention of tumor recurrence at the suture
line, especially when patients cannot tolerate a lobectomy or
further lung resection, has the potential to improve surgical
management of lung cancer in the future. The overall goal
of this study was to evaluate the feasibility of a delayed
drug delivery system to prevent the local growth and estab-
lishment of lung cancer cells in vivo, so as to assess the
potential for future intraoperative application to achieve dis-
tribution of antineoplastic agents to sites at increased risk for
occult microscopic malignant disease. In this article we have
established proof of concept for this approach by successfully
demonstrating that bioabsorbable 1- to 5-mm-diameter pacli-
taxel-loaded poly-(D,L-lactic-co-glycolic acid) (Pax-PLGA)
microspheres exhibit delayed drug release as quantified by
using a paclitaxel enzyme-linked immunosorbent assay
(ELISA), induce apoptosis in lung cancer tumor cells in vitro,
and prevent the local growth and establishment of lung can-
cer tumor cells in vivo.
Materials and Methods
The Harvard School of Public Health Standing Committee on Ani-
mals approved this animal study. All animals received humane careThe Journal of Thorin compliance with the ‘‘Guide for the care and use of laboratory
animals’’ published by the National Institutes of Health.
Cell Culture
The murine Lewis lung carcinoma cell (LLC) line was a gift from
J. Folkman (Children’s Hospital, Boston, Mass). LLCs were grown
to confluence in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), 1% penicillin/
streptomycin (all reagents from Invitrogen, Carlsbad, Calif) at
37C in a 5% CO2 humidified atmosphere, and greater than 95%
viability was confirmed before use.
Preparation of PLGA microspheres
The fabrication techniques used to create the PLGA microspheres
were modified from Edlund and Albertsson7 and Wang and co-
workers.8 Briefly, 0.5 g of 75:25PLGA (AbsorbablePolymer Interna-
tional, Birmingham, Ala) was dissolved in 4 mL of dichloromethane
(Sigma–Aldrich, St Louis, Mo), and 42.5 mg of paclitaxel (MP Bio-
medical, Irvine, Calif) solubilized in 85 mL of dimethyl sulfoxide
(DMSO; Sigma–Aldrich) was added and vortexed. Only DMSO
wasadded for unloaded control PLGAmicrospheres. The polymer so-
lution was placed in 10 mL of 5% polyvinyl alcohol (Spectrum, Gar-
dena, Calif), vortexed, and stirred overnight. The microspheres were
collected and washed 3 times in 50 mL of deionized water before be-
ing lyophilized and stored at235C.
Scanning Electron Microscopy
Several million spheres were diluted in diH2O, placed on a silicon
slide, and allowed to dry overnight before coating with gold. Scan-
ning electron microscopy (SEM) was performed at 40 kV by using
a JSM 6400 Scanning ElectronMicroscope at375 and3750 objec-
tive (JEOL, Tokyo, Japan).
Paclitaxel ELISA
The concentration of paclitaxel released from microspheres into the
surrounding media was assessed by using a solid-phase competitive
inhibition ELISA kit (Hawaii Biotech, Aiea, Hawaii). One million
microspheres suspended in 50 mL of minimal essential medium
(Cellgro, Herndon, Va) were placed on a 0.2-mm Anopore mem-
brane tissue culture insert (Nalge Nunc, Rochester, NY) in 150
mL of media. Media were removed for analysis after 1, 3, 5, 7, 10,
15, and 20 days, with replacement of media in the bottom well to
ensure a constant concentration gradient. Anti-paclitaxel antibody
with bound free paclitaxel was washed from the plates, and remain-
ing anti-paclitaxel antibody was bound to alkaline phosphatase–
labeled anti-mouse immunoglobulin conjugate. The resultant color
change was measured by using a VersaMax ELISA microplate
reader (Molecular Devices, Sunnyvale, Calif) at an absorbance of
405 nm, with greater intensity correlating to less competitive inhibi-
tion and thus lower paclitaxel concentrations.
In Vitro Tumor Cell Proliferation Assays
Inhibition of LLC cell growth was determined by using an MTT
(3-[4,5-dimethylthiazol-2-yl] 2,5-diphenyltetrazolium bromide)
cell proliferation assay. Briefly, 33 103 per well LLCs were seeded
in 96-well plates in DMEMwithout FBS. After being serum starved
overnight, the cells were treated with paclitaxel alone, control PLGA
microspheres, or Pax-PLGAmicrospheres in fresh media containingacic and Cardiovascular Surgery c Volume 135, Number 5 1015
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were present in each experiment. At 3, 5, and 7 days, individual
wells were treated for 2 hours at 37C with 50 mL of thiazolyl
blue tetrazolium bromide (MTT, Sigma–Aldrich) dissolved in
PBS (Sigma–Aldrich). Absorbance values measured at 570 nm
were normalized to a standard curve to determine the number of
viable cells in situ.
Apoptosis Assay
Induction of apoptosis was assessed by means of propidium iodide
(PI) staining, followed by flow cytometric analysis, as described
previously.9,10 One million LLC cells alone, LLCs with 2 3 106/
mL Pax-PLGA microspheres or control PLGA microspheres, or
LLCs in media containing 100 ng/mL paclitaxel were incubated
for 4 days in DMEM containing 10% FBS before harvesting. After
washing in PBS–0.05% bovine serum albumin (BSA; Fisher Scien-
tific, Houston, Tex), cells were fixed in 3 mL of 70% ethanol on ice
for 2 hours, centrifuged at 400g, washed with cold PBS–BSA, and
resuspended in 300 mL of PI staining solution containing 1 mg/mL
RNAase A (ABgene, Rochester, NY) and 1.6 mg/mL PI (Sigma–
Aldrich) dissolved in PBS–BSA. Cells were incubated for 30
minutes at 37C before flow cytometric analysis was performed,
whereby cells containing fragmented DNA were detected and quan-
tified as apoptotic.
In Vivo Model of Subcutaneous Tumor Growth
C57BL/6J (B6) female mice (Jackson Laboratory, Bar Harbor, Me)
of 18 to 22 g were anesthetized by means of isoflurane inhalation in
all experiments. LLCs (7.5 3 105) were coinjected into the subcu-
taneous tissues of the upper back of B6 mice with 100 3 106
unloaded PLGA microspheres, Pax-PLGA microspheres (50 3
106 and 100 3 106 doses), or 100 mL of PBS alone. Paclitaxel-
loaded microspheres were kept separate from the LLC tumor cells
until immediately before loading of each individual syringe. This
method ensured that tumor cells and microspheres were colocalized
at the injection site similar to the approximation of microspheres and
occult microscopic disease at the resection margin. To control for
the effects of paclitaxel exposure during injections, control samples
of LLCs were also coinjected with 2.5 mg of paclitaxel (greater than
the amount of paclitaxel necessary to inhibit the growth of lung
cancer tumor cells by 50% [IC50]) suspended in 100 mL of Cremo-
phor EL [BASF Corporation, Florham Park, NJ]/ethanol (50/50 byvolume, as is done clinically). Animals were monitored for associ-
ated chemotherapy toxicity and weight loss. After 3 weeks, mice
were killed, and a blinded observer assessed tumor weight and
animal toxicity.
Statistics
Data are expressed as means 6 standard error unless otherwise
indicated. Differences between treatment groups were evaluated
by using the Student t test.
Results
Pax-PLGA Microspheres
Pax-PLGA microspheres were prepared as detailed above
and analyzed with SEM for size, porosity, and integrity.
SEM revealed that microspheres were intact spheres of uni-
form shape ranging in size from 1 to 5 mm in diameter (Fig-
ure 1). There was little evidence of porosity, thus suggesting
the capacity for prolonged drug release over an extended pe-
riod of time. A greater than 90% encapsulation efficiency of
paclitaxel within Pax-PLGA microspheres was confirmed
through high-performance liquid chromatography analysis.
Pax-PLGA Microspheres Exhibit High-dose, Long-
term Release of Paclitaxel
Timely and sufficient drug release is critical for effective an-
titumor activity. In vitro MTT cell proliferation assays with
tumor LLCs were performed with growth in 10% and 0% se-
rum, serving as positive and negative controls, respectively,
to determine the IC50. The IC50 for growth of tumor LLCs in-
cubated with paclitaxel alone was approximately 10 ng/mL
(Figure 2). This was observed for the 3-, 5-, and 7-day assays
and is indicative of the estimated paclitaxel dose that must be
released from Pax-PLGA microspheres to inhibit LLC tumor
growth. Complete inhibition of tumor growth required higher
doses of paclitaxel, as evidenced by minimal to no growth at
paclitaxel concentrations of greater than 100 ng/mL.
The kinetics of paclitaxel release over 20 days was mea-
sured by using a quantitative paclitaxel ELISA assay to deter-
minewhether sufficient levels of paclitaxelwere released from
Pax-PLGA microspheres. Figure 3 shows that Pax-PLGAFigure 1. Poly-(D,L-lactic-co-glycolic acid)
microsphere characteristics imaged by means of
SEM. A, Microspheres are of uniform shape
(375 magnification). B, SEM imaging reveals
microspheres to be 1 to 5 mm in diameter (3750
magnification).
1016 The Journal of Thoracic and Cardiovascular Surgery c May 2008
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Azouz et al Cardiopulmonary Support and PhysiologyFigure 2. Dose–response curve for in vitro inhibi-
tion of tumor cell growth by paclitaxel. Three-,
5-, and 7-day proliferation assays demonstrating
effective growth inhibition of LLCs when pacli-
taxel is added to the media are shown. Viable
cell numbers are the average of 8 wells in this
representative experiment (n 5 3). The plotted
IC50 values are the concentration at which cell
growth is inhibited by 50% compared with the
positive control. Error bars reflect the standard er-
ror of the mean. *Statistical significance versus
positive control: P < .01 by Student t test. FBS,
Fetal bovine serum.microspheres demonstrate an initial burst effect that results in
6.8 mg/mL of paclitaxel delivered within the first 5 days of in-
cubation. However, after 10 days, release becomes more
steady, with an increase in concentration of approximately
1.4mg/mL per 5-day incubation period. At 20 days, the cumu-
lative release of paclitaxel from 1 3 106 Pax-PLGA micro-
spheres was 11.9 mg/mL. These results demonstrate that
Pax-PLGAmicrospheres exceed the dose of paclitaxel release
required for LLC cytotoxicity by nearly 1000-fold.
Dose-dependent Inhibition of LLC Proliferation
In Vitro Through Pax-PLGA Microspheres
LLC cells (3 3 103) per well were grown in 10% serum and
incubated with increasing doses of Pax-PLGA microspheres
to test the hypothesis that Pax-PLGAmicrospheres can effec-
tively prevent growth of lung cancer tumor cells because of
paclitaxel release,. Tumor viability was determined by using
the standard MTT assay after coincubation for 3, 5, and 7
Figure 3. Cumulative paclitaxel release from poly-(D,L-lactic-co-
glycolic acid) (Pax-PLGA) microspheres quantitatively determined
by means of paclitaxel enzyme-linked immunosorbent assay. After
Pax-PLGA microspheres release an initial burst of drug, consistent
release is maintained for at least 20 days. Error bars represent the
standard deviation of the mean. These data are the result of 3 sep-
arate experiments.The Journal of Thoradays. As evident in Figure 4, A, cultures treated with Pax-
PLGA microspheres demonstrated a marked dose-dependent
inhibition of tumor growth. Although cell numbers are small
in the day 3 positive control cultures (10% serum), the
number of viable tumor cells that remain after coculture
with all doses of Pax-PLGA microspheres is less than the
day 3 IC50 because of effective early growth inhibition.
This early effect on tumor cell growth is likely the result of
the initial burst effect, at which even a concentration of 0.3
Pax-PLGA microspheres per tumor cell releases sufficient
paclitaxel (10.4 ng/mL) to exceed the 10 ng/mL paclitaxel
concentration required for tumor inhibition at day 3 (Figure 4,
B). However, similar to the results obtained with paclitaxel
alone, more definitive prevention of tumor cell growth in
day 5 and day 7 cultures required an initial local paclitaxel
concentration of greater than 100 ng/mL. Given the delayed
release of paclitaxel from Pax-PLGAmicrospheres, Figure 4,
B, demonstrates that early paclitaxel concentrations do not
exceed 100 ng/mL until concentrations of 4 to 8 micro-
spheres per tumor cell (12–24 3 103 per well) are used,
and this coincides with the complete prevention of tumor
growth noted in vitro at concentrations of 8 or more Pax-
PLGA microspheres per tumor cell (P , .001; Figure 4, A).
Unloaded PLGA Microspheres Alone Are Not
Cytotoxic
Unloaded PLGA microspheres containing only the DMSO
carrier were coincubated with tumor LLCs in a standard
MTT proliferation assay for 3, 5, and 7 days to establish
that tumor growth was not inhibited due to the PLGA micro-
spheres alone. As shown in Figure 5, inhibition of tumor
growth did not occur with unloaded PLGA microspheres
alone, demonstrating that tumor cytotoxicity was not due to
the polymer itself. In addition, control PLGA microspheres
treated for 5 days with MTT did not bind MTT nonspecifi-
cally, and thus the polymer did not interfere with calculations
of tumor cell viability (data not shown).cic and Cardiovascular Surgery c Volume 135, Number 5 1017
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loaded poly-(D,L-lactic-co-glycolic acid) (Pax-
PLGA) microsphere inhibition of lung cancer
growth in vitro. A, Proliferation assay demonstrat-
ing that effective growth inhibition of LLCs by pac-
litaxel microspheres occurs at concentrations of
greater than 8 microspheres per tumor cell. The
plotted IC50 values represent 50% of the prolifera-
tion of the positive control proliferation from the
specified day. Error bars for viable cell numbers
represent the standard error of the mean for 8
wells. These data are representative of 3 separate
experiments. *P < .001 compared with the posi-
tive control. B, Estimated paclitaxel released
from Pax-PLGA microspheres based on ELISA
drug release curve at days 3, 5, and 7. FBS, Fetal
bovine serum.Pax-PLGA Microspheres Induce Apoptosis of Tumor
Cells In Vitro
LLC morphology was examined after incubation with one
million Pax-PLGA microspheres versus unloaded PLGA
Figure 5. Poly-(D,L-lactic-co-glycolic acid) (PLGA) microspheres
alone are not cytotoxic. Proliferation assay over 3, 5, and 7 days
demonstrating no effective growth inhibition by control PLGA mi-
crospheres. Error bars represent the standard error of the mean for
viable cell numbers in 8 wells. These data are representative of 3
separate experiments. FBS, Fetal bovine serum.1018 The Journal of Thoracic and Cardiovascular Surgery c Mmicrospheres per milliliter of media to determine whether
tumor apoptosis was induced by coculture with Pax-PLGA
microspheres. As shown in Figure 6, A, phase contrast
microscopy of tumor LLCs after a 4-day coculture with
Pax-PLGA microspheres was consistent with significant
LLC apoptosis, as evident by membrane blebbing, chromatin
condensation, and haloing. These changes were not evident
in LLCs cultured with control unloaded PLGA microspheres
(Figure 6, B). Similarly, cell-cycle analysis of LLCs by using
PI flow cytometric staining demonstrated a significant in-
crease in the percentage of apoptotic LLCs after a 4-day co-
culture with Pax-PLGA microspheres or paclitaxel alone
compared with LLCs cultured with control PLGA micro-
spheres or media alone (P , .05; n 5 3; Figure 6, C).
Pax-PLGA Microspheres Inhibit Tumor Growth
In Vivo
In vivo efficacy of Pax-PLGA microspheres was assessed in
a murine subcutaneous tumor model, whereby injection of
750,000 tumor LLCs results in the development of palpable
subcutaneous tumor nodules within 1 week, with rapid tumor
growth requiring death within 2 to 3 weeks.11 In this modelay 2008
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analysis. Phase contrast microscopy of day 4 LLC
cultures in the presence of paclitaxel-loaded
poly-(D,L-lactic-co-glycolic acid) (PAX-PLGA) mi-
crospheres (A) or control poly-(D,L-lactic-co-gly-
colic acid) (PLGA) microspheres (B) before PI
staining is shown (310 magnification). C, Per-
centage of tumor LLCs with apoptotic genomic
DNA, as determined by means of flow cytometric
propidium iodide staining and cell-cycle analysis,
after 4-day coculture with Pax-PLGA or control
PLGA microspheres.the subcutaneous injection of tumor LLCs with 50 3 106 or
100 3 106 Pax-PLGA microspheres significantly inhibited
tumor growth (0.497 6 0.183 and 0.187 6 0.083 g) com-
pared with 2.91 6 0.411 g for LLCs with control unloaded
PLGA microspheres and 3.37 6 0.433 g for LLCs alone
(P , .001, Figure 7). In fact, more than 70% of the animals
Figure 7. In vivo inhibition of tumor growth in the presence of
paclitaxel-loaded poly-(D,L-lactic-co-glycolic acid) (Pax-PLGA)
microspheres. Tumor weight at 3 weeks after subcutaneous injec-
tion of 750,000 tumor LLCs alone, tumor with unloaded poly-(D,
L-lactic-co-glycolic acid) (PLGA) microspheres, and tumor with
low or high doses of Pax-PLGA microspheres in C57BL/6 mice
are shown. Error bars represent the standard error of the mean.
*P< .001 compared with LLCs alone by means of the Student t test.The Journal of Thoratreated with Pax-PLGA microspheres had minimal to no
evidence of tumor implantation or growth after coinjection
of 100 3 106 Pax-PLGA microspheres. No mice coinjected
with LLCs and paclitaxel in Cremophor EL/ethanol exhibited
significant inhibition of tumor growth compared with that
seen in untreated control animals (P 5 .175, n 5 6). These
findings indicate that the brief exposure of LLCs to paclitaxel
within the syringe during injection was not responsible for
preventing primary tumor establishment in animals receiving
Pax-PLGA. Furthermore, toxicity was not clinically apparent
in any animals treated with Pax-PLGA microspheres, as wit-
nessed by changes in hair loss, weight, appetite, or activity
level. Thus locally delivered chemotherapy through Pax-
PLGA microspheres can significantly reduce the growth
and establishment of lung carcinoma in vivo in this subcuta-
neous model of microscopic malignant disease, without clin-
ical evidence of systemic toxicity.
Discussion
Surgical resection is well established as the standard of care in
the treatment of early-stage non–small cell lung cancer. How-
ever, depending on the size of the tumor and the extent of sur-
gical resection, local recurrence rates range from 9% to
24%.1,2,5,6,12 Although sublobar resection, compared with
lobectomy, appears to be associated with lower perioperative
morbidity andmortality with better preservation of lung func-
tion,13 the risk of local recurrence is directly related to the dis-
tance from the tumor to the surgical resection margin and is
increased after limited wedge resection or when the surgicalcic and Cardiovascular Surgery c Volume 135, Number 5 1019
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many patients with limited pulmonary reserve cannot tolerate
a lobectomy, yet wide margins are not possible given tumor
size or anatomic location. In cases in which margins are less
than 1 cm, El-Sherif14 demonstrated that local recurrence
was nearly twice that of patients in which the margin was
greater than 1 cm, with a mean follow-up of only 20 months.
Although local recurrence rates as low as 6.25% have been re-
ported after wedge resection and external radiation treatment,
patients were followed for only 7 months, the radiation field
includes normal bystander lung tissue, and a comparison
with equivalent surgical patients not treated with radiation
therapywas not included, making it difficult to assess the ben-
efits of intraoperative radiotherapy versus the risk of radiation
exposure to both the patient and surgical staff.3 Similarly, Lee
and colleagues4 used I125-labeled brachytherapy seeds se-
cured to the resection margin and achieved a local recurrence
rate of 5.71% with a more extensive follow-up of 34 months;
however, application of I125-labeled seeds and the safety is-
sues associated with the use and handling of a radioactivema-
terial were both difficult and cumbersome. Furthermore, only
patients with ‘‘a minimum gross margin of grater than 1 cm’’
were included in the study, thereby eliminating those patients
at greatest risk for local recurrence.
Given the challenge posed by recurrent disease at the sur-
gical margin, the current article demonstrates that locally de-
livered chemotherapy through microspheres deterred the
growth and establishment of lung carcinoma in both in vitro
and in vivo tumor models used for assessing the growth
potential of small tumor burdens. Furthermore, Pax-PLGA
microspheres effectively release active drug and induce apo-
ptosis in lung cancer cells at the site of delivery. As such, these
results support the concept of potentially using a microsphere
drug delivery system to locally treat microscopic tumor foci at
the lung resection margin. Paclitaxel ELISA demonstrated
a considerable burst effect previously observed in PLGA mi-
crospheres8 that might be beneficial in early targeting of ‘‘in-
transit’’ micrometastatic disease near the resection margin. It
is clear, however, that effects on healing of the resection site
in the setting of locally delivered chemotherapy will require
critical assessment, particularly because breakdown of the
polymer into lactic and glycolic acid monomers15 could pro-
duce an inflammatory response and inhibit wound healing.
These potential deleterious effects are minimized by the use
of very small doses of polymer and drug at a given site. Sub-
cutaneously injected mice have shown no evidence of skin
irritation, hair loss, malaise, weight loss, or associated toxicity
after exposure to either the unloaded PLGA or Pax-PLGA
microspheres for several weeks, suggesting that the delayed
nature of polymer breakdown and drug release might mitigate
this risk.
Previous studies have attempted to treat large established
tumors by directly injecting high doses of paclitaxel-loaded
microspheres16 or nanospheres17,18 into the primary tumor.1020 The Journal of Thoracic and Cardiovascular Surgery c MaThe limited success of this approach is likely due to the inabil-
ity to reach adequate drug levels at all parts of the tumor,
given the local diffusion of drug from the spheres. In contrast,
this article proposes that a microsphere drug delivery system
could potentially be used to treat microscopic tumor foci in
a small defined area by locally delivering effective doses of
paclitaxel directly to a limited number of occult tumor cells
present within close proximity to the surgical margin. Con-
tinuous release of paclitaxel from the described Pax-PLGA
microspheres suggests that tumor growth and establishment
could be prevented when microspheres are localized and de-
liver paclitaxel at sufficient concentration to result in tumor
cell death. The in vitro and in vivo studies presented here sug-
gest that prevention of tumor growth is possible, with a readily
achievable concentration of 10 to 100 microspheres per antic-
ipated tumor cell. Concentrating delivery of antineoplastic
drugs within 1 cm of the surgical margin can thereby ensure
sufficient local drug levels within the area of the lung with
the highest risk of local recurrence while requiring signifi-
cantly less total drug than would be necessary after systemic
administration. This is particularly true because previous mu-
rine studies have demonstrated that systemically adminis-
tered paclitaxel results in limited amounts of chemotherapy
being delivered to lung tissue.19 Less than 0.4% of the sys-
temically administered dose of paclitaxel was detectable in
lung tissue 24 hours after intravenous injection, whereas the
paclitaxel concentration was 3 to 13 times greater in the liver
and small intestine.19 Additionally, 40% of paclitaxel is ex-
creted within 24 hours, further limiting the exposure of occult
microscopic disease at the surgical margin in the lung to pac-
litaxel.20 These findings demonstrate thatminimal amounts of
systemically administered paclitaxel are delivered to the site
at greatest risk for lung cancer recurrence, the surgical resec-
tion margin. In contrast, Pax-PLGA microspheres release
drug locally and continuously for more than 20 days. Subcu-
taneous injection of Pax-PLGAmicrospheres and lung cancer
cells demonstrates that one hundred million Pax-PLGA
microspheres delivers a cumulative equivalent dose of 238
mg of paclitaxel per mouse over 3 weeks at the site of micro-
scopic disease and reliably inhibits the local establishment
and growth in vivo. This total dose is comparable with the
10 mg/kg systemic dose commonly used in mouse recipients
and remains well below the murine maximum tolerated dose
of 1000 mg.21 These results provide strong evidence that
localization of Pax-PLGA microspheres at the surgical resec-
tion margin will reliably prevent local tumor recurrence.
The current study establishes the feasibility and proof of
concept that Pax-PLGA microspheres can locally delivery
chemotherapy and effectively prevent tumor cell growth
and establishment in a localized area. Nevertheless, investi-
gations must be performed to study the long-term drug
release profile of the microspheres and the effective radius
of tumoricidal effect caused by released drug before human
application is explored. Understanding the kinetics of drugy 2008
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microspheres are both key features of ongoing study of drug
delivery systems. In addition, subsequent projects are now in
progress to study the effect of drug-eluting polymers on
wound healing and to optimize the localization of polymers
to the resection line. This proof of concept has provided
a foundation for multiple research venues with the ultimate
goal of decreasing local recurrence rates after the surgical
resection of early stage lung cancers.
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